Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surgical management of giant skin tumor - A case report.

Annales de chirurgie plastique et esthetique·2023

Same author

[CONSERVATIVE TREATMENT OF MAYER-ROKITANSKY-KÜSTER-HAUSER SYNDROME. REVIEW OF LITERATURE AND OUR EXPERIENCE].

Akusherstvo i ginekologiia·2016

Same author

[Genital haemorrhage in children and adolescent girls--a management algorythm].

Akusherstvo i ginekologiia·2016

Same author

[ORAL CONTRACEPTIVES AND MOOD/SEXUAL DISORDERS IN WOMEN].

Akusherstvo i ginekologiia·2015

Same author

[Vaginismus and our experience in treating this sexual problem].

Akusherstvo i ginekologiia·2013

Same author

Adipocytokines during pregnancy and postpartum in women with gestational diabetes and healthy controls.

Journal of endocrinological investigation·2013

Search research articles

Related Experiment Video

Updated: May 14, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

[Metformin efficiency for the adolescent PCOS treatment].

S Kedikova, M Sirakov, M Boyadzhieva

Akusherstvo I Ginekologiia

|February 9, 2013

Summary

This summary is machine-generated.

Metformin effectively treats Polycystic Ovary Syndrome (PCOS) in adolescents, improving insulin resistance and regulating menstrual function. This study highlights Metformin as a promising therapeutic option for managing this complex condition in young females.

More Related Videos

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Related Experiment Videos

Last Updated: May 14, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Area of Science:

Endocrinology
Reproductive Medicine
Metabolic Disorders

Context:

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder in adolescents, presenting diagnostic and therapeutic challenges.
Insulin resistance and hyperinsulinemia are key pathophysiological factors in PCOS.
Limited experience exists with insulin sensitizers for adolescent PCOS treatment in certain regions.

Purpose:

To evaluate the efficacy of Metformin in treating adolescent Polycystic Ovary Syndrome (PCOS).

Summary:

A prospective study involved 55 girls (13-18 years) diagnosed with PCOS according to 2010 criteria.
After six months of Metformin (850 mg twice daily), 80% of patients showed improved insulin resistance, and 77.8% experienced regulated menstrual function.
High incidence of overweight (66.7%) and insulin resistance (90.5%) were observed in the study cohort.

Impact:

Metformin demonstrates significant potential in managing key metabolic and reproductive disturbances in adolescent PCOS.
This research provides valuable data on Metformin's utility, particularly in regions with limited prior experience.
Findings support Metformin as a viable treatment option for improving health outcomes in adolescent females with PCOS.